Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE (Conformité Européenne) Mark approval for its DESolve® 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.

Orlando Regional Medical Center is the first hospital in Florida to utilize the Corindus CorPath System.

Some experts suggest FFR has a role in CABG because of its potential to spare patients a complicated surgery as well as cut costs.

ACE is proud to be referenced as a pioneer of accreditation standards in the new health policy statement from the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography (ACC/AHA/SCAI). The policy statement defines new standards for structured reporting of clinical and operational data in the cardiac catheterization laboratory. With the new policy statement, ACC/AHA/SCAI notes the “increasing importance of accreditation of cardiac catheterization laboratories.”

The Detroit Medical Center (DMC) is the first in the Midwest to use a new, state-of-the-art system for treating Coronary Artery Disease (CAD).

OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the COMBO Stent for the treatment of coronary lesions in the setting of routine clinical care. The registry enrolled 1,000 patients at nine European high-volume percutaneous coronary intervention centers in France, Latvia, Luxembourg, The Netherlands, United Kingdom and Spain.

WASHINGTON, DC – March 27, 2014 –A new angiographic analysis of the CHAMPION PHOENIX trial examined the incidence and impact of stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI). Results of the study were released today and will be presented March 30 at the American College of Cardiology 63rd Annual Scientific Session.

WASHINGTON, D.C., March 28, 2014 – With the unmatched flexibility to measure radiation peak skin dose in real time, Toshiba America Medical Systems, Inc.’s Dose Tracking System is the latest advancement in optimizing dose management for its InfinixTM-i cardiovascular X-ray systems during adult and pediatric interventional procedures.